Covidien plc

Covidien — Merger or Acquisition (August 2014)

21 slides from Covidien's merger presentation, Aug 6, 2014

  1. Slide 1: Filed by Medtronic, Inc. pursuant to Rule 425

    Filed by Medtronic, Inc. (SEC File No.: 001-07707) pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Covidien plc Form S-4 File No.: 333-197406 Date: August 6, 2014

  2. Slide 2: Medtronic Positioned to Execute

    Medtronic Positioned to Execute Creating Long-Term Value in Healthcare * Improving operational execution to deliver consistent results * Uniquely positioned to expand our market-leading franchises through three differentiated strategies: 1. Therapy Innovation: Delivering strong launch cadence of mea

  3. Slide 3: Medtronic Today

    Medtronic Today Pacing Advanced MiniMed® asa c= eae Energy 5306 doa = Defibrillation Revenue Mid-Single e ‘Advisa MRI™ Growth: Digits oe PEAK® go PlasmaBlade 9, A om i ee Viva™ CRT-D Operating & é % Financial & ‘“ fi Leverage Pain Stim > 2 Atrial o ze Fibrillation ©) g POO 200 - 400 bps 3 ~ 5 Restor

  4. Slide 4: Delivering on Commitments

    Delivering on Commitments And Strengthening our Competitive Position FY14 FY14 Guidance Actual Highlights * Meaningful product launches including the MiniMed® 530G, Reveal LINQ™ Revenue 43-4% tox $3.6% and CoreValve® + FY14 Emerging Markets growth of 14% * Established Cardiocom® and Cath Lab Managed

  5. Slide 5: Medtronic Growth Strategies

    Medtronic Growth Strategies Strategies to Address Universal Hea Universal Medtronic HC Needs Strategies Improve 5 clinical outcomes | Therapy } Innovation Expand (3 Operational, access Execution Optimize cost and efficiency Globalization Ithcare Needs Sources of Growth GROWTH VECTOR #1: Strong upcom

  6. Slide 6: Growth Vector #1: New Therapies

    Growth Vector #1: New Therapies Medtronic R&D Pipeline ™S 8 IN.PACT® Admiral® SFA BN usesdyaie —— > 3 — > Evolut™ R H 200 projects worth $30B+ in a 28 2K CE Mark: FY15/16 er incremental revenue over L Micra™ - next 5 years ERNE 8 ioe byend of tas —> B sp, Resolute Onyx™ 8 dy Cetneis Next-Gen Interbo

  7. Slide 7: Growth Vector #2: Emerging Markets

    Growth Vector #2: Emerging Markets Making Changes to Realize O EM SG&A Spend Millions +16% + Increased investment $638 + BU and region alignment and $475 responsibility Underserved EM Premium: Attractive Opportunity P * Aligning around customers. * Technology already exists + Granular focus within E

  8. Slide 8: Growth Vector #3: Integrated Health Solutions

    Growth Vector #3: Integrated Health Solutions Quantifying Value & Quantifying Value & Expanding Offerings Expanding Offerings Understand Economic Value of i = innovation >; Naan Broaden Innovation Time Horizon to Ensure Value is : Rethinking Blood Conservation (RBC®) Realized Surgical Synergy™ Smart

  9. Slide 9: Growth Vectors Expected to Deliver Mid-Single Digit Growth

    Growth Vectors Expected to Deliver Mid-Single Digit Growth FY14 MDT Sources of Growth Growth Contribution FYISE MDT FY14 to FY15 Growth / Contribution Change Expectation New 180 bps Therapies Emerging 145 bps Markets 30 bps TOTAL 3.6: MEDTRONIC 10% Note: All revenue estimates assume constantcurrency

  10. Slide 10: Executing on Operating Expense Reduction Initiatives

    ~—_ Executing on Operating Expense Reduction Initiatives PRODUCT COST REDUCTION Mig /Supply FYO8-FY12: ry Process i { . * Defensive: Mitigate pricing pressure & ae | fi DRM } Accomplished maintain 75-76%! gross margins ~ —_— Maintained * Offensive: Enable product tiering & Gross Margins support valu

  11. Slide 11: Rewarding Shareholders with Distributions

    Rewarding Shareholders with Distributions Cash Priorities to Shareholders Overview DIVIDENDS S&P 500 Dividend Aristocrat Index member; 35 years of consecutive dividend increases $0.80 Dividend more than doubled over the past 5 years $0.40 ae Pt ae Over $1 billion in dividend a | | | | \ payments in

  12. Slide 12: Generating Significant Free Cash Flow

    Generating Significant Free Cash Flow $21B FY10-FY14 FY15-FY19E * Expected adjusted FCF generation over next 5 years equal to 40% of current market cap? * Consistently generate > 20% FCF / revenue * Returning 50%+ of FCF to shareholders * Remain focused on improving U.S. cash Note: Adjusted free cas

  13. Slide 13: Commitment to Return 50% of Free Cash Flow

    Commitment to Return 50% of Free Cash Flow! $ Billions $62B? 60 40 40%? = ~$25B+ , {8 | 0 . Current Market Cap Expected Free Cash Flow, Expected Capital Expected Return to Next 5 Years. Deployment, Next 5 Years Shareholders, Next 5 Years 1. Adjusted free cash flowis operating cash flow minus capital

  14. Slide 14: Covidien Overview

    Covidien Overview Highly Strategic and Compelling Acquisition * Accelerates Medtronic’s three core strategies of Therapy Innovation, Globalization, and Economic Value * Covidien’s impressive portfolio of industry-leading products enhances Medtronic’s portfolio, offers greater breadth across clinical

  15. Slide 15: Combination Results in Strategic Diversification

    Combination Results in Strategic Diversification MEDTRONIC FY14 REVENUE cROM Coronary ‘Structural Heart Endo wortho/spine wuNeuro ‘Surgical Tech Diabetes COVIDIEN REV Advanced Surgical General Surgical Peripheral Vascular Patient Care ‘Nursing Core Patient Monitoring Airway & Vent Neurovascular 1. B

  16. Slide 16: Covidien Transaction Summary

    Covidien Transaction Summary Acquisition of Covidien for $42.9 billion in cash ($16.1 billion) and Medtronic stock ($26.8 billion based on Medtronic’s closing stock price on June 13, 2014, the last trading day prior to the announcement of the acquisition) — Covidien shareholders to own ~30% of the c

  17. Slide 17: Medtronic — Covidien Key Facts

    Medtronic — Covidien Key Facts Additional Resources Key Websites * Global MedTech Leader: http://www.globalmedtechleader.com/home * Medtronic Investor Relations: htto://investorrelations.medtronic.com/phoenix.zhtm|?c=76126&p=irol- IRHome Key Documents * Deal Announcement: http://www.globalmedtechlea

  18. Slide 18: Disclaimers

    Disclaimers NO OFFER OR SOLICITATION This communication is not intended to and does not constitute an offer to sell or the solicitation of an offer to subscribe for or buy or an int subscribe for any securities or the solicitation of any vote or approval in any jurisdiction pursuant to the acquisiti

  19. Slide 19: Disclaimers (cont'd)

    Disclaimers (cont'd) PARTICIPANTS IN THE SOLICITATION ‘Medtronic, New Medtronic and Covidien and certain of their respective directors and executive officers and employees may be considered solicitation of proxies from the respective shareholders of Medtronic and Covidien in respect of the transacti

  20. Slide 20: Disclaimers (cont'd)

    Disclaimers (cont'd) Cautionary Statement Regarding Forward-Looking Statements Statements contained in this communication that refer to New Medtronic's, Medtronic’s and/or Covidien's estimated or anticipated future estimated synergies, or other non-historical facts are forward-looking statements tha

  21. Slide 21: Disclaimers (cont'd)

    Disclaimers (cont'd) Statement Required by the Irish Takeover Rules The directors of Medtronic accept responsibility for the information contained in this document. To the best of the knowledge and belief ‘Medtronic (who have taken all reasonable care to ensure that such is the case), the informatio

Covidien — Merger or Acquisition (August 2014) on 6ix